Nymox Pharmaceutical NYMXF
OTC NYMXF
$0.04 -0.02 (-33.33%)
As of: Oct 23, 2026 · 9:30 AM EDT

Nymox Pharmaceutical (NYMXF) Other Accumulated Expenses (2025)

Updated

Nymox Pharmaceutical's Other Accumulated Expenses came in at $659,249 for Q4 2025.

Analysis

Nymox Pharmaceutical (NYMXF) Other Accumulated Expenses (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 Nymox Pharmaceutical 6.12 Mn 5.93 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 659,249.00
API Access

Nymox Pharmaceutical Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=NYMXF&period=max&api_key=YOUR_API_KEY